You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameS-Adenosylmethionine
Accession NumberDB00118  (NUTR00052)
TypeSmall Molecule
GroupsApproved, Nutraceutical
Description

Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

Structure
Thumb
Synonyms
SynonymLanguageCode
(3S)-5'-[(3-amino-3-Carboxypropyl)methylsulfonio]-5'-deoxyadenosine, inner saltNot AvailableNot Available
[1-(Adenin-9-yl)-1,5-dideoxy-beta-D-ribofuranos-5-yl][(3S)-3-amino-3-carboxypropyl](methyl)sulfoniumNot AvailableNot Available
AcylcarnitineNot AvailableNot Available
AdoMetNot AvailableNot Available
S-(5'-Deoxyadenosin-5'-yl)-L-methionineNot AvailableNot Available
S-adenosyl-L-methionineNot AvailableNot Available
S-AdenosylmethionineNot AvailableNot Available
SAMNot AvailableNot Available
SAMeNot AvailableNot Available
Salts
Name/CAS Structure Properties
S-Adenosylmethionine butanedisulfonate
Thumb Not applicable DBSALT000873
S-Adenosylmethionine disulfate ditosylate
Thumb Not applicable DBSALT000875
S-Adenosylmethionine disulfate monotosylate
Thumb Not applicable DBSALT000876
S-Adenosylmethionine disulfate tosylate
Thumb Not applicable DBSALT000874
S-Adenosylmethionine tosylate
Thumb Not applicable DBSALT000872
Brand names
NameCompany
Sam-SulfateNatrol
SAMeNot Available
SAMe Rx-MoodNature's Plus
Brand mixturesNot Available
Categories
CAS number29908-03-0
WeightAverage: 399.445
Monoisotopic: 399.145063566
Chemical FormulaC15H23N6O5S
InChI KeyMEFKEPWMEQBLKI-AIRLBKTGSA-O
InChI
InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/p+1/t7-,8+,10+,11+,14+,27?/m0/s1
IUPAC Name
[(3S)-3-amino-3-carboxypropyl]({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl})methylsulfanium
SMILES
C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=CN=C12
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassOrganooxygen Compounds
ClassCarbohydrates and Carbohydrate Conjugates
SubclassGlycosyl Compounds
Direct parentPurine Nucleosides and Analogues
Alternative parentsGlycoamino Acids and Derivatives; Pentoses; Alpha Amino Acids and Derivatives; Purines and Purine Derivatives; Amino Fatty Acids; Aminopyrimidines and Derivatives; Primary Aromatic Amines; N-substituted Imidazoles; Oxolanes; Tetrahydrofurans; Secondary Alcohols; 1,2-Diols; Carboxylic Acids; Enolates; Polyamines; Ethers; Monoalkylamines
Substituentsalpha-amino acid or derivative; pentose monosaccharide; purine; imidazopyrimidine; aminopyrimidine; pyrimidine; primary aromatic amine; monosaccharide; n-substituted imidazole; tetrahydrofuran; oxolane; imidazole; azole; secondary alcohol; 1,2-diol; carboxylic acid derivative; polyamine; carboxylic acid; enolate; ether; primary amine; primary aliphatic amine; alcohol; organonitrogen compound; amine
Classification descriptionThis compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.
Pharmacology
IndicationS-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
PharmacodynamicsS-adenosylmethionine is an intermediate metabolite of methionine. Its involvement in methylation assists in cellular growth and repair, maintains the phospho-bilipid layer in cell membranes. It also helps in the maintenance of the action of several hormones and neurotransmitters that affect mood. Highest concentration are found in the brain and the liver.
Mechanism of actionS-Adenosylmethionine (SAMe) is a natural substance present in the cells of the body. It is a direct metabolite of the essential amino acid L-methionine. SAMe plays a crucial biochemical role in the body by donating a one-carbon methyl group in a process called transmethylation. SAMe, formed from the reaction of L-methionine and adenosine triphosphate catalyzed by the enzyme S-adenosylmethionine synthetase, is the methyl-group donor in the biosynthesis of both DNA and RNA nucleic acids, phospholipids, proteins, epinephrine, melatonin, creatine and other molecules.
AbsorptionS-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Significant first-pass metabolism in the liver. Approximately 50% of S-Adenosylmethionine (SAMe) is metabolized in the liver. SAMe is metabolized to S-adenosylhomocysteine, which is then metabolized to homocysteine. Homocysteine can either be metabolized to cystathionine and then cysteine or to methionine. The cofactor in the metabolism of homocysteine to cysteine is vitamin B6. Cofactors for the metabolism of homocysteine to methionine are folic acid, vitamin B12 and betaine.

SubstrateEnzymesProduct
S-Adenosylmethionine
Not Available
CystathionineDetails
S-Adenosylmethionine
Not Available
CysteineDetails
S-Adenosylmethionine
Not Available
MethionineDetails
S-Adenosylmethionine
Not Available
HomocysteineDetails
S-Adenosylmethionine
Not Available
S-AdenosylhomocysteineDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityIrritating to mucus membranes and upper respiratory tract. Can cause CNS depression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ubiquinone BiosynthesisMetabolicSMP00065
Methylhistidine MetabolismMetabolicSMP00715
Mercaptopurine Metabolism PathwayDrug metabolismSMP00609
Phenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00327
Nicotinate and Nicotinamide MetabolismMetabolicSMP00048
Carnitine SynthesisMetabolicSMP00465
Spermidine and Spermine BiosynthesisMetabolicSMP00445
Betaine MetabolismMetabolicSMP00123
Aromatic L-Aminoacid Decarboxylase DeficiencyDiseaseSMP00170
Catecholamine BiosynthesisMetabolicSMP00012
Histidine MetabolismMetabolicSMP00044
HistidinemiaDiseaseSMP00191
Tryptophan MetabolismMetabolicSMP00063
Tyrosine hydroxylase deficiencyDiseaseSMP00497
Prolidase Deficiency (PD)DiseaseSMP00207
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)DiseaseSMP00188
Glycine N-methyltransferase DeficiencyDiseaseSMP00222
Non Ketotic HyperglycinemiaDiseaseSMP00223
Tyrosinemia, transient, of the newbornDiseaseSMP00494
Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]DiseaseSMP00506
Hyperprolinemia Type IIDiseaseSMP00360
Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
HawkinsinuriaDiseaseSMP00190
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
DimethylglycinuriaDiseaseSMP00484
Monoamine oxidase-a deficiency (MAO-A)DiseaseSMP00533
3-Phosphoglycerate dehydrogenase deficiencyDiseaseSMP00721
Methionine MetabolismMetabolicSMP00033
Prolinemia Type IIDiseaseSMP00208
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
Glycine and Serine MetabolismMetabolicSMP00004
Dopamine beta-hydroxylase deficiencyDiseaseSMP00498
Hyperornithinemia with gyrate atrophy (HOGA)DiseaseSMP00505
Arginine and Proline MetabolismMetabolicSMP00020
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)DiseaseSMP00362
Ornithine Aminotransferase Deficiency (OAT Deficiency)DiseaseSMP00363
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Tyrosine MetabolismMetabolicSMP00006
AlkaptonuriaDiseaseSMP00169
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
L-arginine:glycine amidinotransferase deficiencyDiseaseSMP00507
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
Hyperprolinemia Type IDiseaseSMP00361
HypermethioninemiaDiseaseSMP00341
Tyrosinemia Type IDiseaseSMP00218
SarcosinemiaDiseaseSMP00244
Hyperglycinemia, non-ketoticDiseaseSMP00485
Creatine deficiency, guanidinoacetate methyltransferase deficiencyDiseaseSMP00504
Disulfiram Action PathwayDrug actionSMP00429
Azathioprine Action PathwayDrug actionSMP00427
Thioguanine Action PathwayDrug actionSMP00430
Mercaptopurine Action PathwayDrug actionSMP00428
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.8102
Blood Brain Barrier - 0.8894
Caco-2 permeable - 0.7307
P-glycoprotein substrate Substrate 0.7584
P-glycoprotein inhibitor I Non-inhibitor 0.9664
P-glycoprotein inhibitor II Non-inhibitor 0.993
Renal organic cation transporter Non-inhibitor 0.9295
CYP450 2C9 substrate Non-substrate 0.8308
CYP450 2D6 substrate Non-substrate 0.8224
CYP450 3A4 substrate Substrate 0.5753
CYP450 1A2 substrate Non-inhibitor 0.8308
CYP450 2C9 substrate Non-inhibitor 0.8396
CYP450 2D6 substrate Non-inhibitor 0.9192
CYP450 2C19 substrate Non-inhibitor 0.8457
CYP450 3A4 substrate Non-inhibitor 0.9731
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9647
Ames test Non AMES toxic 0.6899
Carcinogenicity Non-carcinogens 0.9417
Biodegradation Not ready biodegradable 0.9486
Rat acute toxicity 2.5758 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9755
hERG inhibition (predictor II) Non-inhibitor 0.7962
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral200 mg
CapsuleOral50 mg
Capsule, delayed releaseOral200 mg
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Sam-e 400 mg tablet0.86USDtablet
CVS Pharmacy sam-e 400 mg tablet0.79USDtablet
Sam-e 200 mg tablet0.59USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
boiling point78 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.19ALOGPS
logP-2ALOGPS
logP-5.3ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)1.71ChemAxon
pKa (Strongest Basic)9.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area182.63 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity96.23 m3·mol-1ChemAxon
Polarizability40.37 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Takayasu Tsuchida, Fumihiro Yoshinaga, Shinji Okumura, “Method for producing S-adenosylmethionine or methylthioadenosine by yeast.” U.S. Patent US3962034, issued November, 1971.

US3962034
General Reference
  1. Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol. 2000 Apr;32(4):385-9. Pubmed
  2. Fodinger M, Horl WH, Sunder-Plassmann G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol. 2000 Jan-Feb;13(1):20-33. Pubmed
  3. Roje S: S-Adenosyl-L-methionine: beyond the universal methyl group donor. Phytochemistry. 2006 Aug;67(15):1686-98. Pubmed
  4. Loenen WA: S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans. 2006 Apr;34(Pt 2):330-3. Pubmed
  5. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP: S-Adenosylmethionine and methylation. FASEB J. 1996 Mar;10(4):471-80. Pubmed
External Links
ResourceLink
KEGG CompoundC00019
PubChem Compound34756
PubChem Substance46505280
ChemSpider31983
ChEBI15414
ChEMBLCHEMBL1088977
PharmGKBPA164754994
HETSAM
Drugs.comhttp://www.drugs.com/cdi/s-adenosylmethionine.html
PDRhealthhttp://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/sad_0231.shtml
WikipediaS-Adenosylmethionine
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSshow(35.5 KB)
Interactions
Drug Interactions
Drug
DesvenlafaxineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
KetoprofenIncreased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
SulindacS-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
TramadolIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
TranylcypromineIncreased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
TrazodoneIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
TrimipramineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
VenlafaxineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
WarfarinAdditive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
ZolmitriptanUse of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Food InteractionsNot Available

Targets

1. Glycine N-methyltransferase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: cofactor

Components

Name UniProt ID Details
Glycine N-methyltransferase Q14749 Details

References:

  1. Rowling MJ, Schalinske KL: Retinoid compounds activate and induce hepatic glycine N-methyltransferase in rats. J Nutr. 2001 Jul;131(7):1914-7. Pubmed
  2. Luka Z, Cerone R, Phillips JA 3rd, Mudd HS, Wagner C: Mutations in human glycine N-methyltransferase give insights into its role in methionine metabolism. Hum Genet. 2002 Jan;110(1):68-74. Epub 2001 Dec 7. Pubmed
  3. Rowling MJ, McMullen MH, Chipman DC, Schalinske KL: Hepatic glycine N-methyltransferase is up-regulated by excess dietary methionine in rats. J Nutr. 2002 Sep;132(9):2545-50. Pubmed
  4. Moller MT, Samari HR, Fengsrud M, Stromhaug PE, oStvold AC, Seglen PO: Okadaic acid-induced, naringin-sensitive phosphorylation of glycine N-methyltransferase in isolated rat hepatocytes. Biochem J. 2003 Jul 15;373(Pt 2):505-13. Pubmed
  5. Uthus EO, Brown-Borg HM: Altered methionine metabolism in long living Ames dwarf mice. Exp Gerontol. 2003 May;38(5):491-8. Pubmed

2. S-adenosylmethionine decarboxylase proenzyme

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: cofactor

Components

Name UniProt ID Details
S-adenosylmethionine decarboxylase proenzyme P17707 Details

References:

  1. Dudkowska M, Stachurska A, Grzelakowska-Sztabert B, Manteuffel-Cymborowska M: Up-regulation of spermidine/spermine N1-acetyltransferase (SSAT) expression is a part of proliferative but not anabolic response of mouse kidney. Acta Biochim Pol. 2002;49(4):969-77. Pubmed
  2. Ndjonka D, Zou Y, Bi X, Woster P, Walter RD, Luersen K: The activator-binding site of Onchocerca volvulus S-adenosylmethionine decarboxylase, a potential drug target. Biol Chem. 2003 Aug;384(8):1195-201. Pubmed
  3. Notari S, Lucchi R, Traversa U, Fabbri E, Poli A: Reversible changes in goldfish brain polyamine concentrations and synthetic enzymes after cold exposure. Brain Res. 2004 May 1;1006(2):241-7. Pubmed
  4. Yerlikaya A, Stanley BA: Structural basis for the inactivation of AdoMetDC K12R mutant. Protein Pept Lett. 2006;13(3):313-7. Pubmed

3. S-adenosylmethionine synthase isoform type-2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: cofactor

Components

Name UniProt ID Details
S-adenosylmethionine synthase isoform type-2 P31153 Details

References:

  1. Mudd SH, Cerone R, Schiaffino MC, Fantasia AR, Minniti G, Caruso U, Lorini R, Watkins D, Matiaszuk N, Rosenblatt DS, Schwahn B, Rozen R, LeGros L, Kotb M, Capdevila A, Luka Z, Finkelstein JD, Tangerman A, Stabler SP, Allen RH, Wagner C: Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. J Inherit Metab Dis. 2001 Aug;24(4):448-64. Pubmed
  2. Farrar C, Clarke S: Altered levels of S-adenosylmethionine and S-adenosylhomocysteine in the brains of L-isoaspartyl (D-Aspartyl) O-methyltransferase-deficient mice. J Biol Chem. 2002 Aug 2;277(31):27856-63. Epub 2002 May 22. Pubmed
  3. Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, Avila MA: L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003 May 30;278(22):19885-90. Epub 2003 Mar 26. Pubmed
  4. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, Caballeria J, Avila MA, Mato JM: Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology. 2003 Apr;124(4):940-8. Pubmed

4. Cystathionine beta-synthase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: activator

Components

Name UniProt ID Details
Cystathionine beta-synthase P35520 Details

References:

  1. Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP: Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry. 2001 Sep 4;40(35):10625-33. Pubmed
  2. Jacobs RL, Stead LM, Brosnan ME, Brosnan JT: Hyperglucagonemia in rats results in decreased plasma homocysteine and increased flux through the transsulfuration pathway in liver. J Biol Chem. 2001 Nov 23;276(47):43740-7. Epub 2001 Sep 14. Pubmed
  3. Choumenkovitch SF, Selhub J, Bagley PJ, Maeda N, Nadeau MR, Smith DE, Choi SW: In the cystathionine beta-synthase knockout mouse, elevations in total plasma homocysteine increase tissue S-adenosylhomocysteine, but responses of S-adenosylmethionine and DNA methylation are tissue specific. J Nutr. 2002 Aug;132(8):2157-60. Pubmed
  4. Evande R, Blom H, Boers GH, Banerjee R: Alleviation of intrasteric inhibition by the pathogenic activation domain mutation, D444N, in human cystathionine beta-synthase. Biochemistry. 2002 Oct 1;41(39):11832-7. Pubmed

5. S-adenosylmethionine synthase isoform type-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: cofactor

Components

Name UniProt ID Details
S-adenosylmethionine synthase isoform type-1 Q00266 Details

References:

  1. Carretero MV, Latasa MU, Garcia-Trevijano ER, Corrales FJ, Wagner C, Mato JM, Avila MA: Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: protective effect of S-adenosylmethionine. Biochem Pharmacol. 2001 May 1;61(9):1119-28. Pubmed
  2. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC: Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 2002 Aug;16(10):1292-4. Epub 2002 Jun 7. Pubmed
  3. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ: Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3065-70. Epub 2003 Mar 11. Pubmed
  4. Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, Avila MA: L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003 May 30;278(22):19885-90. Epub 2003 Mar 26. Pubmed
  5. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, Caballeria J, Avila MA, Mato JM: Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology. 2003 Apr;124(4):940-8. Pubmed

6. Catechol O-methyltransferase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: cofactor

Components

Name UniProt ID Details
Catechol O-methyltransferase P21964 Details

References:

  1. Lee BW, Sun HG, Zang T, Kim BJ, Alfaro JF, Zhou ZS: Enzyme-catalyzed transfer of a ketone group from an S-adenosylmethionine analogue: a tool for the functional analysis of methyltransferases. J Am Chem Soc. 2010 Mar 24;132(11):3642-3. Pubmed
  2. Rutherford K, Le Trong I, Stenkamp RE, Parson WW: Crystal structures of human 108V and 108M catechol O-methyltransferase. J Mol Biol. 2008 Jun 27;380(1):120-30. Epub 2008 Apr 23. Pubmed

Enzymes

1. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Caro AA, Cederbaum AI: Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93. Pubmed
  2. Cederbaum AI: Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol. 2010 Mar 21;16(11):1366-76. Pubmed

2. Spermidine synthase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Spermidine synthase P19623 Details

References:

  1. Cyriac J, Haleem R, Cai X, Wang Z: Androgen regulation of spermidine synthase expression in the rat prostate. Prostate. 2002 Mar 1;50(4):252-61. Pubmed
  2. Dejima H, Kobayashi M, Takasaki H, Takeda N, Shirahata A, Samejima K: Synthetic decarboxylated S-adenosyl-L-methionine as a substrate for aminopropyl transferases. Biol Pharm Bull. 2003 Jul;26(7):1005-8. Pubmed
  3. Franceschetti M, Fornale S, Tassonia A, Zuccherelli K, Mayer MJ, Bagni N: Effects of spermidine synthase overexpression on polyamine biosynthetic pathway in tobacco plants. J Plant Physiol. 2004 Sep;161(9):989-1001. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08